Studies May Lend Support To Xarelto Lawsuit Claims

July 05, 2016 – – TheProductLawyers.com reports on research that may lend support to plaintiff claims in the lawsuits against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals. An apparent link between the heightened risk for catastrophic bleeding episodes and use of the new-generation anticoagulant has spurred concern.

The FDA granted approval to Xarelto in 2011, and it was hailed by many as a breakthrough in blood clot prevention. Originally, the drug was approved for treatment of those suffering from pulmonary embolism or deep vein thrombosis and as a clot preventative in individuals recuperating from knee and hip replacement surgeries. It was additionally approved for use as a stroke preventative in patients with atrial fibrillation—a cardiac condition.

However, as mounting numbers of patients filed adverse event reports that claimed the drug was responsible for strokes, clots, massive pulmonary embolisms, and both internal and external uncontrollable hemorrhages, opinions veered sharply. Drs. Judy H. Hun and John C. Hwang, aware of the increasing concern, conducted a preliminary empirical study within their practice.

Because they had also prescribed the drug to their own patients, their grounds for concern were well-substantiated. Among those in their care, they noted that three of their patients taking Xarelto at the time had developed “spontaneous vitreous hemorrhage,” also known as eye bleeding. A more thorough evaluation of their patients revealed that the risk of vitreous hemorrhages was most pronounced in those who had switched to Xarelto from more traditional blood thinners.

A more prolonged study, which ended on March 31st, 2012, examined patients using Xarelto, Pradaxa, and warfarin on a national scale. Doctors collected data from a total of more than 46,000 patients who were taking either traditional or new-generation blood thinners—39,607 warfarin; 4,907 Pradaxa; 1,649 Xarelto. Once the data was collated, a clear pattern appeared to emerge. Researchers noted that there was “as much as a 50 percent increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin…[and] a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

In response to a petition for consolidation, the U.S. Judicial Panel on Multidistrict Litigation has combined more than 2,800 cases against Xarelto into multidistrict litigation (MDL) No. 2592. Additional cases are expected to surface against the anticoagulant and drug manufacturers.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011201